Thompson John S, Thacker Leroy, Byrne James
Department of Medicine, University of Kentucky, Lexington, Kentucky 40502, USA.
Transplantation. 2002 Apr 27;73(8):1274-80. doi: 10.1097/00007890-200204270-00015.
The difficulty of transplanting sensitized patients increases proportionally to the panel reactive antibody (PRA) titer. Because of the high likelihood of a positive final crossmatch, these patients are often excluded from a prospective transplant unless there is a 0 HLA-A, -B, -DR mismatch. To address this problem, we developed a computerized algorithm, termed the Kentucky Antibody Testing System (KATS), that predicts class I HLA antigens that would be both "unacceptable" and "acceptable" to the recipient. This report describes the results of a prospective trial among voluntarily participating centers that agreed to share kidneys based on the KATS predictions for patients whose PRA exceeded 40%.
The results of three antibody screens on each patient were compared with the HLA phenotypes of the cells in the panel in 2x2 tables with calculation of chi-square and correlation coefficient statistics. Private, broad, and public antigens were identified and a list of acceptable and unacceptable antigens were entered into the UNOS computer for each patient listed in the KATS sharing algorithm.
Of the total 418 patients meeting the inclusion/exclusion criteria, the largest single group submitted was Black-not-of-Hispanic-origin females. The mean PRA of the patients was 72%. The first transplant via KATS allocation was performed on March 8, 1997. Between that time and the last transplant on July 31, 2000, 145 kidneys were offered to the participating centers and 48 transplants were performed. Of the many reasons listed for not accepting an offer or not transplanting the shared kidney into its intended recipient, only two occurred because of a positive T cell crossmatch and six because of a positive B cell crossmatch. As compared to all other high PRA patients within Southeastern Organ Procurement Foundation who were transplanted during the study period, they were more likely to be non-Caucasian, to be less well matched for private HLA-A, B, and DR antigens, and to have waited for a longer time than the other groups. Although there was a higher incidence of delayed graft function, there was no significant difference in cold ischemia, rejection episodes, or patient or graft survival.
We conclude that KATS, or some other system to prospectively identify a list of acceptable and unacceptable HLA antigens, could improve the access of highly sensitized patients to a successful kidney transplant.
致敏患者的移植难度与群体反应性抗体(PRA)滴度成比例增加。由于最终交叉配型呈阳性的可能性很高,这些患者通常被排除在预期移植之外,除非存在0个HLA - A、- B、- DR错配。为了解决这个问题,我们开发了一种计算机算法,称为肯塔基抗体检测系统(KATS),该算法可预测受体“不可接受”和“可接受”的I类HLA抗原。本报告描述了一项前瞻性试验的结果,该试验在自愿参与的中心进行,这些中心同意根据KATS对PRA超过40%的患者的预测来共享肾脏。
将每位患者的三次抗体筛查结果与细胞库中细胞的HLA表型在2×2列联表中进行比较,并计算卡方和相关系数统计量。确定了私有、广泛和公共抗原,并将可接受和不可接受抗原的列表输入到器官共享联合网络(UNOS)计算机中,用于KATS共享算法中列出的每位患者。
在符合纳入/排除标准的418例患者中,提交数量最多的单一群体是非西班牙裔黑人女性。患者的平均PRA为72%。1997年3月8日进行了首例通过KATS分配的移植手术。从那时到2000年7月31日的最后一例移植手术期间,向参与中心提供了145个肾脏,进行了48例移植手术。在列出的许多不接受供肾提议或未将共享肾脏移植给预定受体的原因中,只有2例是由于T细胞交叉配型呈阳性,6例是由于B细胞交叉配型呈阳性。与在研究期间接受移植的东南器官获取基金会内所有其他高PRA患者相比,他们更有可能是非白种人,在私有HLA - A、B和DR抗原方面的匹配度更低,并且等待时间比其他组更长。虽然移植肾功能延迟的发生率较高,但在冷缺血、排斥反应、患者或移植物存活方面没有显著差异。
我们得出结论,KATS或其他一些前瞻性识别可接受和不可接受HLA抗原列表的系统,可以改善高度致敏患者获得成功肾移植的机会。